잠시만 기다려 주세요. 로딩중입니다.

BV-2 미세아교세포에서 메트포르민 또는 알파-리포산의 염증반응과 NLRP3 인플라마솜 약화에 관한 연구

Metformin or α-Lipoic Acid Attenuate Inflammatory Response and NLRP3 Inflammasome in BV-2 Microglial Cells

대한임상검사과학회지 2020년 52권 3호 p.253 ~ 230
최혜림, Ha Ji-Sun, 김인식, 양승주,
소속 상세정보
최혜림 ( Choi Hye-Rim ) - Konyang University Department of Biomedical Laboratory Science
 ( Ha Ji-Sun ) - Konyang University Department of Biomedical Laboratory Science
김인식 ( Kim In-Sik ) - Eulji University School of Medicine Department of Biomedical Laboratory Science
양승주 ( Yang Seung-Ju ) - Konyang University Department of Biomedical Laboratory Science

Abstract


Alzheimer’s disease (AD) is a chronic and progressive neurodegenerative disease that can be described by the occurrence of dementia due to a decline in cognitive function. The disease is characterized by the formation of extracellular and intracellular amyloid plaques. Amyloid beta (Aβ) is a hallmark of AD, and microglia can be activated in the presence of Aβ. Activated microglia secrete pro-inflammatory cytokines. Furthermore, S100A9 is an important innate immunity pro-inflammatory contributor in inflammation and a potential contributor to AD. This study examined the effects of metformin and α-LA on the inflammatory response and NLRP3 inflammasome activation in Aβ- and S100A9-induced BV-2 microglial cells. Metformin and α-LA attenuated inflammatory cytokines, such as tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6). In addition, metformin and α-LA inhibited the phosphorylation of JNK, ERK, and p38. They activated the nuclear factor kappa B (NF-κB) pathway and the NOD-like receptor pyrin domain containing 3 (NLRP3) inflammasome. Moreover, metformin and α-LA reduced the marker levels of the M1 phenotype, ICAM1, whereas the M2 phenotype, ARG1, was increased. These findings suggest that metformin and α-LA are therapeutic agents against the Aβ- and S100A9-induced neuroinflammatory responses.

키워드

α-lipoic acid; Amyloid beta; Metformin; NLRP3 inflammasome; S100A9

원문 및 링크아웃 정보

등재저널 정보